NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) reported sales of $17.8 billion for the first quarter of 2017, an increase of 1.6 percent as compared to the first quarter of 2016. Operational sales results increased 2.0 percent and the negative impact of currency was 0.4 percent. Domestic sales increased 0.6 percent.

International sales increased 2.8 percent, reflecting operational growth of 3.6 percent and a negative currency impact of 0.8 percent. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.2 percent, domestic sales decreased 0.7 percent and international sales increased 3.4 percent, the company said in a statement.

Worldwide operational results, excluding the net impact of acquisitions and divestitures were driven in part by Acuvue contact lenses, Johnson & Johnson said.

“Johnson & Johnson's first-quarter results are in line with our expectations and we are confident we will achieve the full-year financial guidance we established at the beginning of the year," said Alex Gorsky, chairman and chief executive officer. “The pending acquisition of Actelion demonstrates our ongoing commitment to bringing innovation to patients with significant unmet needs, and provides a unique opportunity for us to expand our portfolio with leading, differentiated in-market medicines and promising late-stage products. We look forward to the associates from Actelion joining the Johnson & Johnson family of companies.”

During the quarter, Johnson & Johnson announced a definitive agreement to acquire Actelion, a leading biopharmaceutical company, for approximately $30 billion.

Worldwide consumer sales of $3.2 billion for the first quarter 2017 represented an increase of 1.0 percent versus the prior year, consisting of an operational increase of 0.8 percent and a positive impact from currency of 0.2 percent, Johnson & Johnson said. Domestic sales increased 4.1 percent; international sales decreased 1.3 percent, which reflected an operational decrease of 1.6 percent and a positive currency impact of 0.3 percent. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 2.3 percent, domestic sales decreased 2.9 percent and international sales decreased 1.9 percent.

Johnson & Johnson’s worldwide vision care sales climbed to $798 billion for the first quarter 2017, an increase of 24.7 percent versus the prior year consisting of an operational increase of 24.5 percent and a currency impact of 0.2 percent. Domestic sales increased 26 percent to $305 million; international sales increased 23.9 percent to $493 million, which reflected an operational increase of 23.6 percent and a currency impact of 0.3 percent.

Worldwide sales of contact lenses and other vision products rose to $683 million, up 6.7 percent from year ago consisting of an operational increase of 6.5 percent and a currency impact of 0.2 percent. Domestic sales of contact lenses increased 5.8 percent to $256 million with an operational increase of 5.8 percent; international sales of contact lenses increased 7.3 percent to $427 million, with an operational increase of 7.0 percent and a currency impact of 0.3 percent.

During the quarter, Johnson & Johnson completed the acquisition of Abbott Medical Optics, a wholly-owned subsidiary of Abbott and global leader in ophthalmic surgery, for approximately $4.3 billion.